Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochem Biophys Res Commun. 2000 Mar 16;269(2):352-6.

Polo-like kinase1, a new target for antisense tumor therapy.

Author information

1
Department of Medicine II, Institut für Mikrobiologie, J. W. Goethe-Universität, Theodor-Stern-Kai 7, Haus 75, Frankfurt, 60590, Germany.

Abstract

The Polo-like kinase 1 (Plk1) is a highly conserved mitotic serine/threonine kinase which is commonly overexpressed in cancer cell lines. Plk1 positively regulates mitotic progression by activating the CDC25C-CDK1 amplification loop and by regulating late mitotic events, primarily the ubiquitin-dependent proteolysis. In the present study, an antisense strategy against Plk1 mRNA was developed to specifically inhibit cell proliferation of cancer cells in cell culture and in the nude-mouse tumor model. Among 41 phosphorothioate antisense oligodeoxynucleotides tested, the 20-mer JWG2000 strongly inhibited expression of Plk1 in cultured A549 cells, leading to loss of cell viability, and exhibited anti-tumor activity in nude mice A549 xenograft. JWG2000 did not inhibit growth and viability of primary human mesangial cells and human amnion fibroblasts.

PMID:
10708555
DOI:
10.1006/bbrc.2000.2291
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center